SCHEMBL1235883

SCHEMBL1235883

CC(C)(c1cc(O)c2c(-c3ccccc3)coc2n1)C1CCCCC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
ALOX15 P16050 2/20 0.35
USP2 O75604 1/20 0.35
TP53 P04637 1/20 0.35
CYP3A4 P08684 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
ALOX12 P18054 1/20 0.35
BRCA1 P38398 1/20 0.35
BLM P54132 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CAMKK2 Q96RR4 2/20 0.33
CAMKK1 Q8N5S9 1/20 0.33
CCKAR P32238 1/20 0.31
CCKBR P32239 1/20 0.31
SIRT1 Q96EB6 1/20 0.31
PSMB8 P28062 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1264611 0.89 ABCB1 (0.40) ALDH1A1ALOX15MAPTHPGDALOX12
SCHEMBL1265973 0.85 CNR1 (0.33)
SCHEMBL1265853 0.83 MEN1 (0.33) ALDH1A1MEN1KMT2ATP53MAPT
SCHEMBL1193258 0.82 ALDH1A1 (0.31) ALDH1A1MEN1KMT2ASMN1; SMN2CAMKK2
SCHEMBL1265703 0.78 CNR1 (0.39) ALDH1A1MEN1KMT2AALOX15USP2
SCHEMBL1236809 0.78 ALDH1A1 (0.43) ALDH1A1MEN1KMT2AALOX15USP2
SCHEMBL1193614 0.73 CAMKK2 (0.39) ALDH1A1ALOX15MAPTHPGDALOX12
SCHEMBL12895241 0.69 CNR1 (0.53) ALDH1A1MEN1KMT2AALOX15USP2
SCHEMBL1192947 0.69 CNR1 (0.30)
SCHEMBL2113418 0.68 CNR2 (0.42) ALDH1A1HPGDSMN1; SMN2RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8431595-B2 Furanopyridine cannabinoid compounds and related methods of use THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-04-30 US claimed
US-20110046176-A1 FURANOPYRIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2011-02-24 US claimed
WO-2011022692-A2 FURANOPYRIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, THE (US) 2011-02-24 WO claimed
US-8431595-B2 Furanopyridine cannabinoid compounds and related methods of use THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-04-30 US disclosed
US-8431595-B2 Furanopyridine cannabinoid compounds and related methods of use THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-04-30 US disclosed
US-8431595-B2 Furanopyridine cannabinoid compounds and related methods of use THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-04-30 US disclosed
US-20110046176-A1 FURANOPYRIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2011-02-24 US disclosed
US-20110046176-A1 FURANOPYRIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2011-02-24 US disclosed
US-20110046176-A1 FURANOPYRIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2011-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046176-A1 FURANOPYRIDINE CANNABINOID COMPOUNDS AND RELATED METHODS OF USE CNR1, CNR2, FAAH ALDH1A1 1175/4885MEN1 2840/4885KMT2A 4401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.